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ABSTRACT
ADAM8 expressionis increasedin the interface tissue around aloosened hip prosthesis and inthe pannus andsynovium of patientswith
rheumatoid arthritis, but its potential role in these processes is unclear. ADAM8 stimulates osteoclast (OCL) formation, but the effects of
overexpression or loss of expression of ADAM8 in vivo and the mechanisms responsible for the effects of ADAM8 on osteoclastogenesis
are unknown. Therefore, to determine the effects of modulating ADAM expression, we generated tartrate-resistant acid phosphatase
(TRAP)–ADAM8 transgenic mice that overexpress ADAM8 in the OCL lineage and ADAM8 knockout (ADAM8 KO) mice. TRAP-ADAM8 mice
developed osteopenia and had increased numbers of OCL precursors that formed hypermultinucleated OCLs with an increased bone-
resorbing capacity per OCL. They also had an enhanced differentiation capacity, increased TRAF6 expression, and increased NF-kB, Erk,
and Akt signaling compared with wild-type (WT) littermates. This increased bone-resorbing capacity per OCL was associated with
increased levels of p-Pyk2 and p-Src activation. In contrast, ADAM8 KO mice did not display a bone phenotype in vivo, but unlike WT
littermates, they did not increase RANKL production, OCL formation, or calvarial fibrosis in response to tumor necrosis factor a (TNF-a)i n
vivo. Since loss of ADAM8 does not inhibit basal bone remodeling but only blocks the enhanced OCL formation in response to TNF-a,
these results suggest that ADAM8 may be an attractive therapeutic target for preventing bone destruction associated with inflammatory
disease.  2011 American Society for Bone and Mineral Research.
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Introduction
W
e previously identified ad isintegrin and metalloprotease 8
(ADAM8) as the ADAM that was most highly expressed in
osteoclast (OCL) precursors
(1) and demonstrated that ADAM8
was expressed at the later stages of OCL precursor differentia-
tion. ADAM8 significantly stimulated OCL formation in mouse
marrowcultures,andknockdownofADAM8levelswithantisense
S-oligonucleotides inhibited OCL formation in mouse bone
marrow cultures treated with 1,25-dihydroxyvitamin D3.
(1) We
further found that the cysteine-rich disintegrin domain of
ADAM8 rather than the metalloprotease activity was responsible
for its OCL stimulatory effects.
(1) These results suggested that
ADAM8 is an autocrine/paracrine factor that induces osteoclas-
togenesis.
ADAM8 also has been reported to have a role in inflammatory
bone loss.
(2,3) ADAM8 expression is upregulated in particle-
induced arthritis,
(2) and Ainola and colleagues have suggested
that ADAM8 may be associated with a variety of inflammatory
arthritides and mediates the bone destruction in these
conditions.
(3) To further clarify the role of ADAM8 in bone
remodeling, we generated tartrate-resistant acid phosphatase
(TRAP)–ADAM8 (TRAP-ADAM8 transgenic mice that overex-
pressed ADAM8 in cells of the OCL lineage to determine if
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169increased expression of ADAM8 targeted to the OCL lineage
results in enhanced OCL formation in vivo and ADAM8 knockout
(KO)micetoassesswhetherlossofADAM8affectednormalbone
remodeling. TRAP-ADAM8 transgenic mice had increased
numbers of OCL precursors that formed hypermultinucleated
OCLs, decreased trabecular bone volume, and normal bone-
formation levels. Enhanced expression of ADAM8 increased
activation of Erk, p38 MAPK, and PI3K, which increased the bone-
resorbing capacity per OCL. In addition, this increased bone
resorbing capacity was associated with increased levels of p-
Pyk2 and p-Src activation. In contrast, knockout of ADAM8 in vivo
did not affect normal bone remodeling but severely blunted the
increase in OCL formation seen with tumor necrosis factor a
(TNF-a) treatment. Taken together, these results suggest that
ADAM8 is an attractive therapeutic target for blocking bone
destruction in inflammatory disease.
Materials and Methods
Materials
Receptor activator of NF-kB ligand (RANKL) and monocyte
colony-stimulating factor (M-CSF) were purchased from R&D
Systems (Minneapolis, MN, USA). CD11b microbeads were
obtained from Miltenyi Biotec (Gladbach, Germany). The rabbit
immunoglobulin against mouse Ki67 was purchased from Dako
Corp. (Carpinteria, CA, USA).All otherchemicals werefrom Sigma
Corp. (St Louis, MO, USA). Antibodies against c-Fos, NFATc1,
cathepsin K, av, b3, cFms, RANK, TRAF6, and CD44 were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to
phosphorylated and total Pyk2, Src, paxillin, Cbl, Erk1/2, JNK, p38
MAPK, Akt, and IkBa were from Cell Signaling Technology
(Danvers, MA, USA), antibodies to b-actin and ATP6v0d2 were
from Abcam, Inc. (Cambridge, MA, USA), and anti-DC-STAMP was
from Trans Genic, Inc. (Fukuoka, Japan).
Generation of TRAP-ADAM8 transgenic mice
To generate mice that overexpress ADAM8 in cells of the OCL
lineage, a TRAP-ADAM8 transgene construct was generated by
insertion of the 2.7-kb murine ADAM8 cDNA (GI:19343645) into
the unique EcoRI site of the pBSpKCR3-mTRAP vector.
(4) This
vector contains the murine TRAP promoter region, including
1294 bp of the 5’-flanking sequence plus the entire 5’
untranslated region (UTR).
(5) The vector also contains part of
the second exon, the second intron, and the third exon of the
rabbit b-globin gene, which provide both a polyadenylation site
and an intron for efficient transgene expression. The 5.8-kb
TRAP-ADAM8 XhoI fragment was microinjected into the male
pronucleus of fertilized one-cell mouse embryos obtained by
mating CB6F1 (C57BL/6 BALB/c) males and females. Injected
embryos were reimplanted into pseudopregnant CD-1 recipi-
ents, and the resulting offspring were screened by polymerase
chainreaction(PCR)fortheTRAP-ADAM8transgeneusingaTRAP
5’-UTR sense primer 5’-GTCCTCACCAGAGACTCTGAACTC-3’ and
an ADAM8 cDNA antisense primer 5’-TCCATAAGACGCTGAG-
CAGCCAG-3’. Southern blot analysis of transgenic founders was
performed to verify transgene structural integrity and to
determine transgene copy number. TRAP-ADAM8 transgenic
mouse lines were maintained on a CB6F1 background. Similar
results were obtained in two independent TRAP-ADAM8
transgenic lines.
Generation of ADAM8 KO mice
To generate ADAM8 KO (ADAM8
 / ) mice, an ADAM8 targeting
vector was derived from pKO NTKV-1901, which contains both a
PGK/neo/BGH cassette for positive selection of homologous
recombinants with G418 and an MC1-tk cassette for negative
selection of nonhomologous recombinants with ganciclovir
(Stratagene, La Jolla, CA, USA). LoxP sites were inserted at both
ends of the PGK/neo/BGH cassette, and 129/SV genomic
fragments containing ADAM8 exons 1 to 17 (nucleotides –
1543 to 7736 of GI:2326260) and 18 to 22 (7737 to 10713) were
inserted at the 5’ and 3’ ends of the neo cassette, respectively. A
third loxP site was introduced into the EcoRI site (3599) in intron
5. The ADAM8 targeting vector was linearized with Ssp I and
electroporated into 129/Sv embryonic stem (ES) cells. Genomic
DNA from ES cell clones resistant to both G418 and ganciclovir
was screened for homologous recombination by long-range PCR
with BGH senseand ADAM8 intron 22 antisense (10782 to 10759)
primers. Southern blot analysis was performed on clones that
were positive by PCR and retained the intron 5 loxP site using a
PGK/neo probe to verify clone purity and integrity of both
genomic arms. C57BL/6 blastocysts were injected with an ES cell
clone carrying a correctly targeted ADAM8 allele and implanted
into pseudopregnant CD-1 recipients. The resulting male
chimeras were bred to C57BL/6 females, and tail genomic
DNA from agouti offspring was screenedby PCRforthe presence
of the targeted ADAM8 allele.
Mice carrying the targeted allele were bred to FVB/N-Tg
(EIIa-cre) mice that express Cre in the germ line (Jackson
Laboratory, Bar Harbor, ME, USA). Cre-mediated recombination
generated both ADAM8
þ/  mice carrying a standard KO allele in
which exons 6 to 17 have been deleted and ADAM8
þ/  mice
possessing a conditional knockout allele containing loxP sites in
introns 5 and 17. The conditional KO mice were not used in this
study. ADAM8
þ/  mice were interbred to generate mice of the
ADAM8 genotypes (þ/þ, þ/ ,a n d / ) used in this study.
Offspring were screened by PCR using a common exon 4 primer
(3297 3320: 5’-GGCTCAAGCTACACAGAGACCTAC-3’), a WT-spe-
cific intron 5 primer (3709 3686: 5’-GGCTACACCGAAAAA-
CCCTGTCTC-3’), and a KO-specific exon 18 primer (7996 7974:
5’-GACAGTGGCACTCCCTCTTGTGG-3’). A Southern blot of ApaLI/
PflFI double restriction digests of genomic DNA from offspring of
each of the genotypes was probed with an ADAM8 genomic
fragment ( 1543 to  277) to verify deletion of exons 6 to 17 in
the KO mice (data not shown). The ADAM8
 /  mouse line was
maintained on a C57BL/6 129/Sv mixed background.
All animal studies were approved by the Institutional Animal
Care and Use Committees at the University of Pittsburgh School
of Medicine, the VA Pittsburgh Healthcare System, and Virginia
Commonwealth University and were conducted in accordance
with the AnimalWelfareAct, the PHS Policyon HumaneCare and
Use of Laboratory Animals, and the U.S. Government Principles for
the Utilization and Care of Vertebrate Animals Used in Testing,
Research, and Training.
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The gross morphologic and microarchitectural traits of the distal
areaof the femur and L5 vertebra were examined by quantitative
mCT. The L5 vertebrae were used to assess histomorphometry of
the trabecular bones, and the femurs were used to measure
mean cortical thickness. Specimens were held with Styrofoam
within plastic vials and positioned within a 25-mm-diameter
acrylic tube. After an initial scout scan, full-length scans were
obtained at an isotropic voxel resolution of 10.5mm using a
commercial scanner (Scanco Viva CT40, Scanco Medical AG,
Bassersdorf, Switzerland) using the following settings:
Energy¼55 kVp, current¼145mA, and integration time-
¼300ms. A total of 300 slices with an increment of 25mm
were obtained on each bone sample starting 1.0mm below the
growth plate inthe areaof the secondary spongiosa. The areafor
analysis was outlined within the trabecular compartment,
excluding the cortical and subcortical bone. Every 25 sections
were outlined, and the intermediate sections were interpolated
with the contouring algorithm to create a volume of interest.
Segmentation values used for analysis were sigma 0.8, support 1,
and threshold 275. A 3D analysis was done to determine bone
volume (BV/TV, %), trabecular number (Tb.N, /mm
2), trabecular
thickness (Tb.Th, mm), and trabecular bone spacing (Tb.Sp, mm).
Cortical bone also was measured on the femur 2mm below the
growth plate, and the same segmentation parameters were used
for analysis.
Bone histomorphometric analyses
Mouse spines and femurs were fixed overnight in 10% buffered
formalin, decalcified in 10% EDTA, embedded in paraffin, and
then sectioned and stained for TRAP activity or with Masson’s
trichrome. Bone histomorphometric parameters from femurs
were determined by measuring the areas at least 0.5mm from
the growth plate, excluding the primary spongiosa and
trabeculae connected to the cortical bone. OCL number per
bone surface (NOc/BS, N/mm
2) and the percentage of OCL
surface to bone surface (OcS/BS, %) were obtained by counting
TRAP
þ cells and by measuring the area in serial 5-mm-thick
sagittal histologic sections of femurs from 20-week-old WT mice.
TRAP
þ cells forming resorption lacunae on the surface of the
trabeculae and containing one or more nuclei were identified as
OCLs. Mineral apposition rates and bone-formation rates were
measured in trabecular bone of the vertebral bodies. A real
measurement and a surface measurement were made by grid-
intersect counting on calibrated digital images by observers
blinded to the treatment group being examined. The abbrevia-
tions for histomorphometric parameters were according to the
recommendation by the American Society of Bone and Mineral
Research Histomorphometry Nomenclature Committee.
(6)
In vitro osteoclastogenesis in cultures of purified early
OCL precursors
Whole bone marrow cells were flushed from long bones of 4- to
20-week-old WT, TRAP-ADAM8 or ADAM8
 /  mice and plated on
100-mm tissue culture plates in a-Minimal Essential Medium (a-
MEM, Gibco BRL Invitrogen, Carlsbad, CA, USA) containing 10%
fetalbovineserum(FBS,Invitrogen).Cellswereincubatedat378C
in 5% CO2 overnight. Nonadherent cells were harvested, and
then CD11b
þ mononuclear cells obtained using Miltenyi Biotec
MACS (Magnetic Cell Sorting) system.
(7) CD11b
þ cells then were
cultured in a-MEM containing 10% FBS plus 10ng/mL of
monocyte colony-stimulating factor (M-CSF) for 2 to 3 days.
These CD11b
þ cells were used as a source of enriched early OCL
precursors. CD11b
þ cells then were cultured in a-MEM
containing 10% FBS in the presence of 50ng/mL of RANKL
(R&D Systems) for 3 to 4 days to generate OCLs, and the level of
OCL formation was determined by counting the number of
TRAP
þ multinucleated cells ( 3 nuclei/cell).Immunoblotting of
extracts from OCL precursors obtained from TRAP-ADAM8,
ADAM8
 / , or WT mice
Lysates from RANKL-treated or control OCL precursors from
TRAP-ADAM8, ADAM8
 / , or WT mice were processed for
Western blot analysis as described previously.
(8) Membranes
then were exposed to primary antibodies overnight at 48C,
washed three times, and incubated with secondary goat
antimouse or antirabbit IgG horseradish peroxidase (HRP)–
conjugated antibody for 1 hour. Membranes were washed
extensively, and an enhanced chemiluminescence detection
assay was performed following the manufacturer’s directions
(Pierce Biotechnology, Rockford, IL, USA). All blots were
quantitated densitometrically, and the results were expressed
relative to control and normalized to b-actin.
In vitro bone resorption assays of cultured OCLs
CD11b
þ cells were cultured on mammoth dentin slices (Wako,
Osaka, Japan) in a-MEMþ10% FCS containing M-CSF and
RANKL. After 14 days of culture, the cells were removed, the
dentin slices were stained with acid hematoxylin, and the areas
of dentin resorption were determined using image-analysis
techniques (NIH Image System).
Treatment of ADAM8
 /  mice with TNF-a
Three-month-old ADAM8
 /  (n¼8) and WT mice (n¼7) were
injected over the calvaria for 5 consecutive days with TNF-a
(1.5 mgi n5 0mL of PBS/day) or PBS alone. On day 6, calvaria were
harvested, fixed in 10% buffered formalin, and processed for
histology, and tissue sections stained for TRAP activity and
analyzed as described earlier.
Statistical analysis
For all cell culture studies, significance was evaluated using a
two-tailed unpaired Student’s t test, with p<.05 considered to
be significant. For the histologic analysis of bones, two-way
analysis of variance (ANOVA) was performed to compare the
differences in all histomorphometric variables among genotypes
and across age. One-way ANOVA was performed to compare the
differences among age groups of each genotype of variables in
which an age-related change was detected. Statistical analysis
was performed using NCSS 2004 and PASS programs (NCSS,
Kaysville, UT, USA).
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TRAP-ADAM8 transgenic mice have increased OCL
formation and decreased trabecular bone volume
We assessed the effects of ADAM8 overexpression on OCLs
in vivo by targeting expression of the murine ADAM8 cDNA to
cells in the OCL lineage using the murine TRAP promoter
(Fig. 1A), which directs efficient expression to OCLs and OCL
precursors.
(5) OCL precursors from these mice then were
screened for ADAM8 expression by Western blot analysis
using a specific antibody to ADAM8. OCL precursors from
TRAP-ADAM8 mice showed approximately 2-fold greater
ADAM8 expression than WT mice (Fig. 1B). In addition, we
generated an ADAM8
 /  mouse as depicted in Fig. 1C to
examine the consequence of ADAM8 deficiency on bone
in vivo.
Quantitative mCT analysis of trabecular areas of the femurs
(Fig. 2A) and 5th lumbar vertebrae (Fig. 2B, C) from TRAP-ADAM8
and WT mice revealed the presence of osteopenia in the TRAP-
ADAM8 mice. As shown in Fig. 2C, D, the vertebral bodies from
TRAP-ADAM8 mice showed markedly decreased total bone
volume compared with WT mice. Morphometric analysis
confirmed that the OCL surface was significantly increased in
TRAP-ADAM8 mice compared with WT mice (Fig. 2E). Bone
volume/total bone volume, trabecular number, and trabecular
thickness were decreased significantly in TRAP-ADAM8 mice,
whereas trabecular spacing was increased (Fig. 2F). However,
there was no significant difference in bone formation or mineral
apposition rates(datanotshown)betweenTRAP-ADAM8andWT
mice. mCT analysis of the fifth vertebrae from TRAP-ADAM8 mice
showed that the trabecular bone fraction [bone area/total area
(BAr/TAr)] was 40% 7% versus 59% 3.5% for WT mice.
Fig. 1. GenerationofTRAP-ADM8transgenic mice.(A)MapoftheTRAP-ADAM8transgeneconstruct.(B)ADAM8expressionlevelsinOCLprecursorsfroma
WTmouseandoffspringfromTRAP-ADAM8mice.ThebonemarrowcellswereculturedwithM-CSFfor3days,andthencellswerecollectedincommercial
lysate buffer (Santa Cruz Biotechnology). ADAM8 expression was determined by Western blot analysis using specific anti-ADAM8 antibody (Millipore
Corporation, Temecula, CA, USA). Similar results were detected in three different lines of mice. (C) Targeting vector for generation of both conditional
and total knockout of the ADAM8 gene. Structure of the (I) WT targeted ADAM8 allele and (II) the targeting vector. The positions of the bovine growth
hormone (BGH) and intron 22 primers used for initial screening of ES cell clones are shown. (III) Structure of the knockout or (IV) conditional knockout
allele of ADAM8 following breeding of mice carrying the initially targeted allele to EIIa-cre transgenic mice. The lack of ADAM8 mRNA expression was
verified in three knockout lines of mice by semiquantitative RT-PCR. GAPDH mRNA also was amplified from each sample as a control for RNA quantity
and integrity.
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numbers of OCLs in response to RANKL
CD11b
þ marrow cells from TRAP-ADAM8 mice formed increased
numbers of OCLs, which contained increased nuclei/OCL
compared with WT littermates (Fig. 3A–D). OCL formation in
marrow cultures from TRAP-ADAM8 mice was evident as early as
1dayafterRANKLadditionandremainedelevatedthroughday6
compared with WT cultures (Fig. 3C). Further, OCL precursor
numbers and proliferation, as measured by TRAP
þ mononuclear
cells and Ki67 staining, respectively, was increased significantly
in marrow cultures from TRAP-ADAM8 mice compared with WT
Fig. 2. Characterization of bones from ADAM8 transgenic mice. (A) Quantitative mCT analysis of trabecular areas of the femurs at 30-week-old mice.
(B) Quantitative mCT analysis of the fifth lumbar vertebrae at 30-week-old mice (anteroposterior view). (C) Quantitative mCT analysis of the fifth lumbar
vertebrae for 30-week-old mice (proximal-distal view). (D) Histologic features of a TRAP-ADAM8 mouse compared with a WT control mouse at 20 weeks of
age. TRAP staining, counterstained with methyl green–thionin. Original magnification  100. (E) Osteoblast surface/bone surface n¼5 mice per group.
 Significant differences (p<.05) between TRAP-ADAM8 and WT mice by Mann-Whitney test. Data represent results from a typical experiment. Similar
results were seen in three independent experiments.
 p<.05 compared with WT mice. ( F) Quantitation of mCT analysis of the fifth lumbar vertebrae from
30-week-old WTandTRAP-ADAM8mice.Thepercentbonevolumepertotalvolume,trabecularbonespacing(mm),andtrabecularbonethickness(2mm)
are shown. Data represent mean values SEM for 15 mice per group, significantly different from WT mice by Mann-Whitney test, p<.05.
ADAM8 AND OSTEOCLAST FORMATION Journal of Bone and Mineral Research 173Fig. 3. OCL precursors from TRAP-ADAM8 mice for increased numbers of OCL in response to RANKL compared with WT mice. (A) Number of TRAP
þ
multinuclear cells per well. Highly purified CD11b
þ cells from WT and TRAP-ADAM8 mice were cultured as described in ‘‘Materials and Methods.’’ Results
areshownasthemean SD.
 p<.01,significantlydifferentfromWT.Similarresultswereseeninfourindependentexperiments.(B)TRAPstainingofOCLs
formed by nonadherent marrow cells. Marrow cells (2 10
5/well) from WT and TRAP-ADAM8 mice were cultured with M-CSF (10ng/mL) and RANKL
(50ng/mL) for 7 days. Note the increased number and size of the OCLs formed in the TRAP-ADAM8 cultures. Original magnification  200. (C) Time course
for OCL formation by TRAP-ADAM8 and WT OCL precursors. CD11b
þ cells from WT and TRAP-ADAM8 mice were cultured in the presence of M-CSF (10ng/
mL) and RANKL (50ng/mL). After 1, 2, 4, or 6 days, after addition of RANKL, cells were stained with TRAP, and TRAP
þ multinucleated cells were counted.
Results are shown as the mean SD for quadruplicate culture.
 p<.05 and
  p<.01, significantly different from WT. Similar results were seen in three
independent experiments. (D) Nuclear number per OCL for TRAP-ADAM8 and WT OCLs. Nuclei per TRAP
þ OCLs were scored in 100 OCLs counted at
random. Results are shown as the mean SD.
 p<.01, significantly different from WT. Similar results were seen in three independent experiments.
(E) Number of TRAP
þ mononuclear cells are increased in TRAP-ADAM8 cultures. CD11b
þ cells from WT and TRAP-ADAM8 mice were cultured in the
presence of M-CSF (10ng/mL) and RANKL (50ng/mL). After 4 days of culture, cells were stained with TRAP, and TRAP
þ mononuclear cells were counted.
Results are shown as the mean SD.
 p<.01, significantly different from WT. Similar results were seen in three independent experiments. ( F) Ki67
þ
mononuclearcellsareincreasedinculturesfromTRAP-ADAM8mice.CD11b
þcellsfromWTandTRAP-ADAM8micewereculturedinthepresenceofM-CSF
(10ng/mL) and RANKL (50ng/mL). After 3, 6, or 9 days of culture, cells were evaluated by immunostaining using an anti-Ki67 antibody. All results are
shown as the mean SEM for quadruplicate culture.
 p<.05, significantly different from WT. Similar results were seen in two independent experiments.
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However, subsequently, the levels of Ki67 positivity of OCL
precursors on days 6 and 9 were similar in TRAP-ADAM8 and WT
cultures (Fig. 3F). Similarly, [
3H]thymidine incorporation in OCL
precursors was increased modestly in marrow cultures from
TRAP-ADAM8 mice compared with WT mice (1949 135 versus
1554 78 cpm/well, p<.05).
Expression of OCL differentiation markers is enhanced in
TRAP-ADAM8 OCL precursors
As shown in Fig. 4A, marrow cultures from TRAP-ADAM8 mice
expressed relatively higher levels of c-Fos and NFATc-1
compared with WT mice on days 2 and 4 after addition of
RANKL. avb3 integrin expression also was increased in TRAP-
ADAM8 OCLs compared with WT OCLs starting at day 3 ofculture
(Fig. 4B). The levels of TRAF6 but not expression of c-Fms and
RANK were increased 1.4 0.1 (mean SEM)–fold in OCL
precursors from TRAP-ADAM8 mice compared with WT mice
(Fig. 4C).
Src tyrosine kinase is activated in TRAP-ADAM8 OCL
precursors
Since ADAM8 binds its cognate receptor, a9b1 integrin, on OCL
precursors,
(9) we then measured integrin signaling in OCL
precursors from TRAP-ADAM8 mice by determining if Pyk2
(Tyr402), Src (Tyr416), Cbl (Tyr731), and paxillin (Tyr118) were
activated in whole-cell lysates of OCL precursors from TRAP-
ADAM8 mice by Western blot analysis. Increased phosphoryla-
tion of Pyk2 and Cbl in TRAP-ADAM8 cells was detected at
5minutes and then slowly decreased, whereas p-Pyk2 and p-Cbl
appeared slowly over 60minutes in WT cells (Fig. 5A). Src
activation also was increased in TRAP-ADAM8 OCL precursors
compared with WT OCL precursors (Fig. 5A). The increased
phosphorylation of Src was detected at the initiation of the
cultures and lost by 60 minute in TRAP-ADAM8 OCL precursors
after incubation with RANKL, whereas there was no change in
total Src. Paxillin phosphorylation was biphasic in WT cells with a
peak at 2minutes, after which it disappeared rapidly and
reemerged at 20minutes. In the TRAP-ADAM8 OCL precursors,
the initial p-paxillin peak was stronger and longer, whereas Pyk2,
Cbl, and paxillin levels were similar in OCLs from TRAP-ADAM8
and WT mice (Fig. 5A).
Activation of the Akt, MAPKs, and NF-kB signaling
pathways is increased in TRAP-ADAM8 OCL precursors
We then determined which of the multiple signaling pathways
implicated in the induction of OCL formation
(10,11) was activated
by overexpression of ADAM8 in OCL precursors. As shown
Fig. 5B, there was increased NF-kB activation in TRAP-ADAM8
cells compared with WT cells with RANKL, as noted by increased
phosphorylation and faster degradation of IkBa in TRAP-ADAM8
OCLprecursors.Thephosphorylation levelsoftheMAPKs,Erk1/2,
and p38 MAPK, and AKT (an indicator of PI3K activation) also
were greater and were more rapid when OCL precursors from
TRAP-ADAM8 mice were treated with RANKL for the indicated
times compared with WT mice (Fig. 5B). RANKL induced Erk1/2
and Akt activation in both WT and TRAP-ADAM8 OCL precursors,
exhibited a sharp peak at 5minutes, disappearing rapidly, but
the degree of activation was significantly higher in TRAP-ADAM8
cells. The pattern of activation of p38 MAPK was similar to Erk1/2
and Akt except that the loss of p-p38 was slower. In contrast,
JNK1 phosphorylation/activation induced by RANKL was similar
in TRAP-ADAM8 and WT OCL precursors.
DC-STAMP is increased on TRAP-ADAM8 OCL precursors
Since OCL precursors from TRAP-ADAM8 mice formed OCLs with
increasednuclei perOCL,wedetermined theexpressionlevelsof
several fusion molecules known to be expressed in OCL
precursors. OCL precursors from TRAP-ADAM8 mice treated
with RANKL had increased expression of DC-STAMP (Fig. 6A).
After 3 days of RANKL treatment, when DC-STAMP expression
peaked in OCL precursor cultures, TRAP-ADAM8 OCL precursors
expressed threefold higher levels of DC-STAMP than medium-
treatedTRAP-ADAM8OCLprecursors (Fig.6A)andfivefoldhigher
than RANKL-treated WT OCL precursors (Fig. 6A). The expression
levels of CD44, CD48, and ATP6v0d2, which peaked on days 5
and 6 of OCL precursor cultures, were only modestly elevated in
TRAP-ADAM8 OCL precursors compared with WT OCL precursors
(Fig. 6B, C).
Bone resorption by TRAP-ADAM8 OCLs is increased
compared with WT OCLs
Bone resorption in marrow cultures from TRAP-ADAM8 mice was
increased fivefold compared with WT cultures (Fig. 6D, F). The
increased resorption in TRAP-ADAM8 cultures was not due solely
to there being more OCLs formed than in WT cultures (Fig. 6E)
but also was due to increased bone resorption per OCL (twofold)
compared with WT cultures (Fig. 6G).
ADAM8 KO mice do not increase OCL formation in
response to TNF-a
We next examined the effects of loss of ADAM8 in vivo on bone
remodeling both under normal conditions and when OCL
formation was stimulated with TNF-a. ADAM8 KO mice do not
display a bone phenotype either in vitro or in vivo under basal
conditions, and the activity of signaling pathways associated
with OCL activity was similar in ADAM8 KO and WT littermates
(data not shown). However, as shown in Fig. 7A, B, when ADAM8
KO mice were treated with TNF-a for 5 days, OCL formation was
minimally increased, whereas in WT littermates, OCL formation
was increased fivefold. Interestingly, calvarial fibrosis induced by
TNF-a in WT mice was markedly decreased in ADAM8 KO mice.
Importantly, TNF-a induced less RANKL production by marrow
stromal cells from ADAM8 KO mice than in those from WT mice
(Fig. 7C). OPG expression levels were similar in ADAM8 KO and
WT stromal cells treated with TNF-a (data not shown). Thus the
blunted OCL response to TNF-a in ADAM8 KO mice can be
explained in part by changes in RANKL/OPG expression. These
results demonstrate that although loss of ADAM8 did not affect
normal bone modeling, it blunted the effects of TNF-a on
osteoclastogenesis and inflammation.
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The ADAMs (ad isintegrin and metalloprotease) are a family of
cell surface proteins related to class III snake venom metallo-
proteases.
(12) The structure of ADAM8 suggests that these
proteins possess both proteolytic and adhesive functions. We
have reported previously that ADAM8 is the major ADAM
expressed in OCLs and that it stimulates osteoclastogenesis in
vitro.
(1) We further demonstrated that the disintegrin domain of
ADAM8 is responsible for its effects on osteoclastogenesis and
that ADAM8 binds to a9b1 on OCL precursors to induce OCL
formation. ADAM8 does not bind to other integrins on OCL
Fig. 4. Expression of OCL differentiation markers by TRAP-ADAM8 OCL precursors treated with RANK. (A) c-Fos, NFATc-1, and cathepsin K expression.
CD11b
þ OCL precursors from WT and TRAP-ADAM8 mice were cultured with M-CSF for 3 days and then with 50ng/mL of RANKL for the indicated times,
and whole-cell lysates (30mg of protein/lane) were subjected to immunoblot analysis using anti-c-Fos, anti-NFATc-1, or anti–cathepsin K antibodies. b-
Actin is shown as a loading control. Similar results were seen in two independent experiments. (B) avb3 expression by OCL precursors from WT and TRAP-
ADAM8 mice. OCL precursors were cultured with RANKL (50ng/mL) for the indicated times, and whole-cell lysates (30mg of protein/lane) were subjected
toimmunoblotanalysisusinganti-avoranti-b3antibody.b-Actinisshownasaloadingcontrol.Similarresultswereseenintwoindependentexperiments.
(C) c-Fms, RANK, and TRAF6 expression by OCL precursors from TRAP-ADAM8 mice. OCL precursors from WT and TRAP-ADAM8 mice were cultured with
RANKL (50ng/mL) for 3 days, and whole-cell lysates (30mg of protein/lane) were subjected to immunoblot analysis using anti-c-Fms, anti-RANK, or anti-
TRAF6 antibody. TRAF6 but not RANK or c-Fms was increased in OCL precursors from TRAP-ADAM8 mice. b-Actin is shown as a loading control. Similar
results were seen in three independent experiments.
176 Journal of Bone and Mineral Research ISHIZUKA ET AL.Fig. 5. Activation of signaling pathways involved in OCL formation and activity in TRAP-ADAM8 and WT OCL precursors. (A) Activation of tyrosine kinases
in OCL precursors. OCL precursors from WT and TRAP-ADAM8 mice were cultured with M-CSF for 3 days and then 50ng/mL of RANKL for the indicated
times, and whole-cell lysates (30mg of protein/lane) were subjected to immunoblot analysis using antibodies recognizing phosphorylated and total
signaling moleculesof Pyk2 (Tyr402), Src (Tyr416), paxillin(Tyr118), andCbl (Tyr731). b-Actinis shownas a loadingcontrol. (B) Activation of theNF-kB, Akt,
andMAPKsignalingpathwaysinOCL precursors fromTRAP-ADAM8mice.OCLprecursorsfromWTandTRAP-ADAM8micewereculturedwith50ng/mLof
RANKL for the indicated times, and whole-cell lysates (30mg of protein/lane) were subjected to immunoblot analysis using antibodies recognizing
phosphorylated and total IkBa (Ser32), Akt (Ser473), JNK (Thr183/Tyr185), p38 MAPK (Thr180/Tyr182), and Erk1/2 (Thr202/try204). b-Actin is shown as a
loading control.
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disintegrin domain.
(1) Further, a9b1 is the only receptor for
ADAM8 on OCL precursors because cells lacking a9 integrin do
not respond to ADAM8 to induce OCL formation.
(9) Recent
studies have suggested an important role for ADAM8 in
pathologic bone destruction associated with inflammatory
conditions such as rheumatoid arthritis (RA) or aseptic loosening
of hip prostheses.
(2,3) However, it is unclear whether ADAM8
mediates these effects in vivo or what would be the
consequences of targeting ADAM8 on normal bone remodeling.
Therefore, we developed transgenic mice with ADAM8 targeted
tocellsoftheOCL lineageusingtheTRAPpromoterandknocked
out ADAM8 by homologous recombination. As shown in Fig. 2,
OCL surface and osteoclastic bone resorption was increased
markedly in TRAP-ADAM8 mice, which resulted in osteopenia.
The osteopenia did not result from decreased bone formation or
inhibited osteoblast activity because osteoblast surface and
bone-formation rates were normal in TRAP-ADAM8 mice. The
Fig. 6. Expression of fusion molecules by OCL precursors and bone resorption by OCLs from TRAP-ADAM8 and WT mice. OCL precursors from WT and
TRAP-ADAM8micewereculturedwithM-CSFfor3daysandthen50ng/mLofRANKLfortheindicatedtimes,andwhole-celllysates(30mg ofprotein/lane)
were subjected to immunoblot analysis using (A) anti–DC-STAMP, (B) anti-CD44, and (C) anti-CD48 or anti-ATP6v0d2 antibodies. b-Actin is shown as a
loading control. Similar results were seen in two independent experiments. (D) Bone-resorption lacunae formed by WT and TRAP-ADAM8 OCLs. OCL
precursors were cultured on dentin slices with 30ng/mL of M-CSF and 100ng/mL of RANKL for 14 days. At the end of the culture period, the dentin slices
were stained with acid hematoxilin to display resorption pits. Original magnification  200. (E) The number of TRAP
þ OCLs per dentin slice. ( F) Resorption
areaperdentinslice.(G)Bone-resorption areaperOCL. Allresultsareshownas themean SDforat leasttriplicatecultures.
 p<.05,significantly different
from WT N.S.¼not significantly different compared with WT. Similar results were seen in three independent experiments.
178 Journal of Bone and Mineral Research ISHIZUKA ET AL.increased OCL formation was due in part to a modest increase in
OCL precursor proliferation, as evidenced both by increased
[
3H]thymidine incorporation and Ki67 staining of early OCL
precursors in the cultures (Fig. 3F). The increased proliferation of
OCLprecursors inTRAP-ADAM8 mice occurred at the early stages
of the bone marrow cultures, consistent with our previous
findings that OCL precursor proliferation only occurs early in
bone marrow cultures induced to form OCLs.
(13) Further, OCL
precursors from TRAP-ADAM8 mice treated with RANKL formed
higher numbers of OCLs than WT animals at similar concentra-
tions of RANKL. However, these OCL precursors do not appear to
be hypersensitive to RANKL because the slopes of the dose-
response curves for OCL precursors from TRAP-ADAM8 mice and
WT mice were similar (Fig. 3A). Consistent with the increased
proliferation of OCL precursors from TRAP-ADAM8 mice, Erk1/2
activation was enhanced in TRAP-ADAM8 OCL precursors
compared with WT OCL precursors (Fig. 5B). Further, as shown
in Fig. 4A, modest increases of ADAM8 expression in OCL
precursors from TRAP-ADAM8 mice ( twofold; Fig. 1A) resulted
in enhanced expression of both c-Fos and NFATc-1 after RANKL
treatment, critical transcription factors required for OCL
differentiation.
(14) This increase in c-Fos and NFATc-1 expression
was not due to increased RANK expression on the surface of OCL
precursors because c-Fms and RANK were not increased
significantly in OCL precursors from TRAP-ADAM8 mice
(Fig. 4C). Interestingly, TRAF6 was increased in OCL precursors
approximately 1.4-fold, which may be responsible for the
increased activity of multiple signaling pathways and enhanced
osteoclastogenesis seen in TRAP-ADAM8 mice.
ADAM8 also enhanced OCL precursor fusion that resulted in
the formation of hypermultinucleated OCLs, which contained
approximately twice as many nuclei per OCL as WT OCL
precursors (Fig. 3D). The enhanced OCL precursor fusion most
likely reflects the increased expression of DC-STAMP in OCL
precursors from TRAP-ADAM8 mice, which was enhanced further
with RANKL treatment (Fig. 6A). DC-STAMP appears to be
increased selectively in TRAP-ADAM8 OCL precursors compared
with other fusion molecules associated with increased OCL
precursor fusion (eg, CD44, CD48, and ATP6v0d2), which were
not increased significantly in TRAP-ADAM8 OCL precursors
(Fig.6B,C).Leeandcolleagues
(15)reportedthatincreasedNFATc-
1 through upregulation of c-Fos results in increased expression
Fig. 7. Responses to TNF-a administration in ADAM8 KO and WT mice. Photomicrographs taken from sections of calveria from WT and ADAM8 KO mice
treated with saline or TNF-a and stained with TRAP and hematoxylin. WT mice demonstrated increased osteclastogenesis, as demonstrated by the
increased numbers of TRAP
þ (red) osteoclasts present in deep resorption cavities and inflammation. These responses were blunted in ADAM8 KO mice
treated with TNF-a (p<.01). (B) OCL perimeter measured in WT and ADAM8 KO mice treated with TNF-a or saline. TNF-a significantly increased OCL
perimeter in WT but not ADAM8 KO mice.
 Significantly different from saline treatment (p<.01). (C) RANKL production by marrow stromal cells from
ADAM8 KO and WT mice. Marrow-adherent cells were isolated and cultured for 2 days with vehicle or TNF-a (10ng/mL). The conditioned media were
harvested and RANKL levels measured with an ELISA assay from R&D Systems (Minneapolis, MN, USA). Results expressed the mean SD for four
determinations.
 Significantly different from saline-treated cultures (p<.01).
DSignificantly different from WT cultures treated with TNF-a.
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these transcription factors, this may explain its capacity to
enhance DC-STAMP expression. Similarly, Kim and colleagues
(16)
also have shown that NFATc-1 induces OCL fusion via
upregulation of DC-STAMP. This is so because the DC-STAMP
promoter contains both AP-1- and NFATc-1-binding sites
necessary for DC-STAMP expression after RANKL stimulation
of OCL formation.
(17) However, it is surprising that ATP6v0d2 also
was upregulated only slightly (1.7-fold) in TRAP-ADAM8 OCL
precursors because NFATc-1 also can enhance expression of this
fusion molecule. Further, the enhanced p38 MAPK signaling in
TRAP-ADAM8 OCL precursors also may contribute to the
hypermultinuclearity of OCLs formed in marrow cultures from
TRAP-ADAM8 mice. We showed recently that enhanced p38
MAPK signaling plays a critical role in the increased nuclear
number per OCL in OCLs expressing the measles virus
nucleocapsid gene.
(18)
OCLs formed in marrow cultures from TRAP-ADAM8 mice had
an increased bone-resorbing capacity per OCL. This increased
bone-resorbing capacity per OCL appears to be multifactorial.
Hypermultinucleation enhances osteoclastic bone resorption.
(19)
Further, increased expression of ADAM8 in OCL precursors
resulted in enhanced expression of avb3 as well as enhanced Src
and paxillin activation. avb3 Integrin plays a critical role in
osteoclastic bone resorption through its effects on the OCL
cytoskeleton andformation ofthe sealingzoneattachment.Cells
lackingavb3haveanimpairedbone-resorbingcapacityandhave
poor attachment to the bone surface owing to abnormal
formation of the actin ring.
(20)
We have shown previously that a GST-ADAM8 disintegrin
fusion protein binds a9b1 and Pyk2, which induces paxillin
phosphorylation.
(21) These results demonstrate that ADAM8/
a9b1 interacts with Pyk2 to enhance signaling through paxillin.
Paxillin is a target for the tyrosine kinase Src, and Src plays a
critical role in osteoclastic bone resorption but not OCL
formation.
(8) Animals lacking Src form increased numbers of
OCLs, but the animals develop osteopetrosis
(22) because Src
kinase plays an important role in cytoskeletal organization and
OCL function. Src is also involved in the regulation of OCL cell
adhesion and motility, as well as cell survival. Further, a key
function of Src in OCLs is to enhance rapid assembly and
disassembly of the podosomes, which are specialized attach-
ment structures on OCLs that are required for bone resorption.
Pyk2 then recruits Src to the activated integrin, in particular,
avb3, which results in phosphorylation of Cbl. Cbl incombination
withphosphatidal inositol3kinase anddynamin playkeyroles in
the development of osteoclastic cell polarity, cell attachment,
and motility.
(23,24) ADAM8 enhances the activity of both Pky2
and Src, which results in enhanced paxillin phosphorylation.
Thus increased expression of ADAM8 in cells of the OCL
lineage results in enhanced osteoclastogenesis owing to
increased OCL precursor proliferation and fusion and enhanced
bone resorption per OCL. The increased bone resorption most
likely reflects increased activation of Pyk2, Src, and paxillin, as
well as increased expression of avb3 per cell. These results
suggest that increased expression of ADAM8 in OCLs associated
with inflammatory bone disease plays a key role in the bone-
destructive process.
Interestingly, ADAM8
 /  mice did not display a bone
phenotype, did not form significantly decreased numbers of
OCLs in vitro, have decreased nuclei per OCL, or display changes
in DC-STAMP, p38 MAPK, or Erk signaling. These results suggest
that loss of ADAM8 during development canbe compensated by
other molecules, which are yet to be identified. In contrast, mice
that lack a9 integrin, the integrin receptor for ADAM8, have an
OCL phenotype.
(9) This suggests that the molecules compensat-
ing for the loss of ADAM8 also may bind a9b1 integrin. Loss of
ADAM8 markedly blunted the increase in OCL formation and
fibrosis seen with TNF-a treatment in vivo and RANKL expression
by stromal cells in vitro (Fig. 7). These results demonstrate a
previouslyunknownroleofADAM8inRANKLproductionbyTNF-
a. These results further suggest that ADAM8 may be a
therapeutictargetforblockinginflammatory bonedestruction.
(1)
Increased expression of ADAM8 enhances OCL formation,
differentiation, and bone resorption per OCL and results in
osteopenia in vivo, whereas loss of ADAM8 in vivo does not
significantly affect normal bone homeostasis but blocks the OCL
stimulatory effects of inflammatory cytokines such as TNF-a,
which is a major cytokine implicated in inflammatory bone
loss.
(25)
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